Expect some pipeline adjustments at
in the coming years, because
thinks the antiviral biotech can expand its horizons while also figuring out a way to address the yearslong Covid pandemic with an expected Phase II launch later this year.
“I would like to take a look at what we have as possibilities coming out of the lab. We have such a strong discovery program,” Rottinghaus told
Endpoints News. “
I don’t think we need to be limited to antivirals here at Enanta; we can take a broader look at some other therapeutic areas.”
For now, though, the former hematology and nephrology clinical development leader at
, which last year was
, is returning to his roots in the infectious disease field.
In undergrad at Kansas State, polyomavirus structural proteins consumed Rottinghaus’ attention. Then it was vaccine work on measles and influenza during medical school and residency at Mayo Clinic. A stint working on HSV came next, as an infectious disease fellow at the University of Alabama at Birmingham in the mid-aughts. Antimicrobials and vaccines took center stage during an eight-year post at
, including a clinical lead role on bacterial infection med
“Big Pharma in the past decade has lost some interest in anti-infectives, which is what caused me to kind of move away as opportunities knocked. When I heard about the opportunity at Enanta, it was actually a fairly easy choice for me,” the CMO said.
In his telling, Rottinghaus is “very excited” or “really excited” about the work ahead, making it clear four times in the first minute of an interview on day three in the new C-suite post.
Covid-19 and respiratory syncytial virus are “right at the top of the list,” he said. Following
Phase I data
on its once-daily oral drug late last month, Enanta will meet with the FDA “in the very near future” to agree on a Phase II program for
, a 3CL protease inhibitor. That trial is slated to be global in scope to “move it forward as quickly as possible,” the new CMO said. Enanta is also in the midst of
Rottinghaus’ former employer, Pfizer, over the Big Pharma’s Covid drug,
Beyond Covid, Rottinghaus will dig into a Phase IIb testing
in adults at high risk for getting infected with RSV. In May, the drug
a mid-stage test in otherwise healthy adults with community-acquired RSV.
→ Things look a little hazier for
’s CD73 candidate
after analysts voice their disppointment with the latest update
on a drug
” at AACR in early 2021.
has now taken command
of Arcus’ clinical development as CMO and presides over a pipeline that, alongside quemliclustat, includes a clutch of cancer drugs like
at the heart of the
$725 million deal
with Gilead. The ex-medical chief at
, Nuyten has also been VP of global product development for oncology at Pfizer and a group medical director for
Bristol Myers Squibb
→ The big names in
’s leadership structure are gradually peeling away as head of R&D
packs his bags
to “pursue other opportunities outside of the Company,” according to a
that provided few details beyond his interim successor, chief innovation officer
. Mammen’s sudden departure late Monday follows that of ex-CSO
, who’s now reshuffling the deck at
, and it comes nearly a year after J&J first
would replace now-executive chairman
at the end of the year as
is set to replace him as SVP, human resources and diversity. Fry started as a systems analyst at the Indianapolis pharma in 1987 and has held his current role since 2011, while Dozier is also a longtime Lilly vet who’s held such roles as general manager, Puerto Rico and chief marketing officer for Japan. At the end of this month,
will leave Bristol Myers
Dozier as Loxo’s chief commercial officer. Tucker joined BMS from
in 2019 as SVP and general manager, US hematology and was elevated to SVP, intercontinental in January.
will only be CEO of
a little while longer,
chairman of Evelo’s board and heading back to
“to help launch, grow, and guide bioplatform companies” as an executive partner. Both appointments will take effect when a successor is named. As founding chief executive, Gill shepherded Evelo
to an IPO
in 2018 and into Phase II trials with its lead program in psoriasis and atopic dermatitis. With the bear market hitting the sector hard, Evelo cushioned the blow with a $79.2 million
in late May.
→ Bristol Myers partner
, an Oxford, UK-based cancer biotech once backed by
has lined up
as CEO. Davis jumps to the top spot here after helping launch
Third Harmonic Bio
as COO; the Novartis and
alum has also been a principal at Flagship.
, the interim chief for the last year, will become PsiOxus’ COO and UK president.
propped open a window into some early data with
for solid tumors, and in the same release, the biotech shared
to CSO and
to chief legal and administrative officer. Both execs arrived last year, with Bialucha originally joining Xilio from
as SVP of research and Frankenfield coming from
to take on the role of general counsel.
will take over
as CEO of The Alliance for Regenerative Medicine on Sept. 6, replacing
Janet Lynch Lambert
. Once part of ARM’s Gene Editing Task Force, Hunt had just taken on the role of chief culture and corporate affairs officer at Xilio in October 2021. He was also chief corporate affairs officer at
from 2016-20 and a public affairs exec with Biogen.
→ Concurrent with its $35 million Series C haul, San Francisco’s
as CEO. Nohaile leaves his CSO post at Flagship’s
and his Big Pharma background consists of multiple roles over a 14-year period at Novartis (including four years as global head of molecular diagnostics) and
(rounding out his tenure as SVP of strategy, commercialization, and innovation). Prellis
with Bristol Myers and
in separate antibody deals earlier this year.
→ Grounded by the FDA with a
on its CAR-T drug
for relapsed/refractory T-cell acute lymphoblastic leukemia and lymphoma,
as chief commercial officer. Big Pharma connections abound with Lo, who led the hematology franchise during his eight years at Novartis; worked on such drugs as
at AstraZeneca and was the pharma giant’s head of global marketing and market access; and became SVP of worldwide hematology for Bristol Myers in 2019 after the
The Appian Way
: Los Angeles-based
off-the-shelf CAR therapies with invariant natural killer T cells (iNKT) and
in a deal worth up to $875 million —
has rolled out
the welcome mat for
as CSO. Damiano wraps up a three-year run at
as VP of biology, and from 2016-18 he was director of therapeutic antibody discovery and translational medicine at
. Ex-Kite and
has sewn up a spot on the board of directors at Appia Bio, a company chaired by Nobel laureate
and led by former
→ Looking to
combo in NSCLC while swiftly sliding
into a penny stock morass,
as CMO. Warner breaks away from Amgen after an 18-year run that ended as executive medical director, group product area lead. Along with tomivosertib, he takes charge of eFFECTOR’s early-stage studies of
in solid tumors and Covid-19.
has signed on
as CMO of
three months ago as it tries to get in the good graces of the FDA with the seizure drug
and its epinephrine oral film
. Truitt, whose first day at Aquestive is Sept. 6, spent 16 years at
before his appointments as medical chief of
in 2018 and
a year later. Meanwhile,
COO and CFO
has joined Aquestive’s board of directors.
→ Big Pharma vet
has been named
EVP, global medicine development and CMO at Chinese antibody biotech
. Germa’s CV reads like a who’s who of the industry: After six years at Eli Lilly, she was clinical lead for breast cancer med
) during her four years at Pfizer. She then jumped to Novartis in 2011, where she rose to senior global program clinical head for
. She then left for Bristol Myers in 2018, staying there for a year before joining AstraZeneca as VP and head of the early development clinical group for oncology.
has settled in
as SVP of business operations at
, which is developing
for endocrine disorders such as classic congenital adrenal hyperplasia. Ramtin joined Spruce in June after three years with
as VP, commercial operations and VP, business operations. Earlier, she was oncology business director at
and had two separate stints at
→ California CAR-T player
has had itself a year with $111 million in Series B
, the addition of board chair
and a growing C-suite
that now includes
as CFO and head of business development. The
vet had been CFO of diagnostics company
since April 2021. ImmPACT Bio has also appointed a chief technology officer (
) and COO (
) in the last few months.
→ Tucked into its Q2 report, natural killer biotech
has been appointed head of CMC. Zhou is the former head of drug product development, cell therapy at
who recently led MS&T (manufacturing sciences & technology) at
; early in her career, she was a scientist at Pfizer and J&J. Just before the bottom fell out of the sector, MiNK went public in October 2021 with a $40 million IPO.
-backed peptide drug design biotech
as chief strategy officer and promoted
to COO. Deshpande joins the Pittsburgh-based company from
, where he served at the helm of the company as CEO. Prior to that stint, Deshpande was chief strategy officer and head of US operations for
and global operations head for the
franchise at Sanofi.
Pachuda joined Peptilogics in 2020, starting as SVP of portfolio and development. Pachuda hopped aboard Peptilogics after a gig at J&J, leading external innovation for the company’s orthopedic device franchise.
→ German CDMO
, which was
a Form 483 for multiple production issues in June,
has brought aboard
as chief of staff and
as corporate general counsel. Sydow was formerly the head of
, where she had a 16-year run. Meanwhile, Nuernberger served as general counsel Europe of
and has had stints at
→ Early cancer screening and detection-focused biotech
AnPac Bio-Medical Science
has ushered in
as co-chairman of the board and co-CEO of the company and
as a member of its board of directors. Cui and Kang’s appointments come as AnPac has re-shuffled some of its board and exec team. AnPac relieved
from his duties as co-chairman and co-CEO and removed
from its board. In addition, the company has re-designated
Chris Chang Yu
as co-CEO and chairman of the board.
→ Bioengineering company
has pulled in
as CFO. Damasio formerly served as VP, finance at
, controller at
and CFO of
→ With the smallpox antiviral
a contract signature from BARDA and talks of potential use in the monkeypox outbreak — after the compassionate-use hubbub in 2014 that involved young Josh Hardy receiving the drug —
as VP, regulatory affairs. Jordan, an Eli Lilly alum, held the role of senior global program regulatory director at Novartis after a string of regulatory posts at
→ Houston-based TCR-T outfit
is bringing in
as VP, technical operations. A former assistant professor at the University of Pittsburgh School of Medicine, Srivastava comes to Alaunos from
, where he was VP, cell therapy development.
as VP of regulatory affairs. McNamara-Cullinane joins from
, where she was SVP of regulatory affairs. Prior to that, McNamara-Cullinane was principal of MMC regulatory consulting at
$12.8 million in cash for
and its “pipeline-in-a-product” in May,
as VP, investor relations and corporate communications. Ochsner was previously an investor relations and communications exec with
→ Just when you think the Maraganore Meter is taking a breather at Peer Review, here he comes again: Former
is making his way
to the board of directors at
. The list of board appointments and advisory roles for Maraganore is as long as your arm, from chairing the board at
to helping out
as a strategic advisor — and beyond.
→ Former HHS Secretary
has popped up over at
as part of the company’s medical advisory board. Azar brings with him a wealth of experience including his time as president of the US division of Eli Lilly and as a board member of BIO. Leading up to his role as HHS secretary under former president
, Azar formerly served as general counsel of HHS starting in 2001.
-led Third Harmonic Bio
is shoring up
its board of directors by appointing
. The current
CEO was Holles’ COO at
and he’s also on the board at
→ Liver disease biotech
to the board of directors. Dable was president and CEO of
after a 22-year career with Bayer, while Alesina is a
vet who is VP, national business development and alliances at Boston Children’s Hospital.
, the company focused on brain health disorders, has signed on
to its board of directors. Bruhn is president, CEO and director of
while Crystal is the president, CEO and director of
and the lead inventor of the
→ Carlsbad, CA-based
as a new member of its board of directors. Getts is the co-founder and CEO of
and has previously had gigs as VP of research at
and co-founder and CSO of